Videos
From Skepticism to Success: Insights Into Biosimilar Market Acceptance
October 13th 2024Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona Cancer Center, discusses the potential of biosimilars and challenges in the US, emphasizing partnerships for market growth.
Promoting Informed Decision-Making Through Biosimilar Awareness
September 8th 2024Ivo Abraham, PhD, RN, University of Arizona Cancer Center, urges stakeholders to provide patient advocacy groups with comprehensive information about specific drugs and drug classes to increase patient understanding of biosimilars and promote informed decision-making.
Bridging Clinical Practice, Health Economics for Improved Patient Access
August 11th 2024Ivo Abraham, PhD, RN, University of Arizona Cancer Center, focused on the cost savings generated by biosimilars and how crucial reinvesting those savings into broader patient access to care is. This approach has the potential to improve health care equity and expand treatment options for patients.
Streamlining Biosimilar Approvals by Balancing Safety, Speed
July 28th 2024Ivo Abraham, PhD, RN, University of Arizona Cancer Center, recognizes the importance of stringent safety measures for biosimilar approvals. However, he advocates for utilizing statistical models and placing emphasis on postmarket safety data collection.
IPD Analytics' Jeffrey Casberg Discusses Recent Biosimilar Approvals
July 14th 2024Jeffrey Casberg, MS, RPh, senior vice president of pharmacy at IPD Analytics, highlights new FDA approvals, the launch of the first tocilizumab biosimilar, and how pharmacy and therapeutics committees approach new pipeline drugs.
Jeffrey Casberg of IPD Analytics Gives Insight on Specialty Drugs in the Pipeline
June 30th 2024In an interview with Jeffrey Casberg, MS, RPh, he discusses 3 promising specialty drugs coming through the pipeline. Casberg explains these drugs offer new treatment options for major diseases and stakeholders should watch for their potential impact on the market.
IPD Analytics' Jeffrey Casberg Says IRA, PBM Legislation Reshape US Drug Costs
June 23rd 2024Jeffrey Casberg, RPh, MS, from IPD Analytics, explains why he believes policy changes and market forces are impacting the cost of drugs, including the Inflation Reduction Act (IRA) and pharmacy benefit manager (PBM) legislation.
